JAK2-突变的克隆性血液形成与静脉血栓塞栓症有关
Rebecca L Zon1,2,3, Aswin Sekar1,2,3, Katharine Clapham4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Blood
|August 5, 2024
概括
不确定潜力的克隆性血液形成 (CHIP) 与发生静脉血栓栓塞 (VTE) 的风险增加有关,特别是在JAK2突变的情况下. 大多数CHIP病例不会改变血栓形成风险,但JAK2突变CHIP显著增加了VTE风险.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 血栓形成研究研究
背景情况:
- 静脉血栓塞栓症 (VTE) 是一个重要的健康问题在老年人,往往缺乏可识别的原因.
- 骨髓质恶性瘤,包括髓增殖性瘤 (MPNs),是已知的VTE的风险因素.
- 不确定潜力的克隆性血液形成 (CHIP),是髓状瘤的前体,在老年人中很普遍,也可能增加VTE风险.
研究的目的:
- 调查CHIP与流行和发生的VTE之间的关联.
- 在CHIP患者中检查基因型特异性VTE风险.
- 澄清CHIP,特别是JAK2突变CHIP在VTE发展中的作用.
主要方法:
- 分析了超过40万个英国生物库样本.
- 评估CHIP和VTE之间的整体和基因型特定关联.
- 统计分析包括危险比率 (HR) 和几率比率 (OR) 与置信区间 (CI).
主要成果:
- CHIP显示,与发生的VTE存在温和的关联 (HR1.17,P=.002),但没有流行VTE (OR1.02,P=.81).
- 发生TET2突变的CHIP与发生的静脉瘤相关 (HR1.33,P=.02).
- JAK2突变与流行性 (OR 6.58,P=4.7×10-5) 和偶发性VTE (HR 4.2,P=1.7×10-5) 都表现出强烈的关联,即使排除未诊断的MPN.
结论:
- 大多数CHIP患者没有增加血栓形成的风险.
- JAK2突变CHIP与VTE风险显著增加有关,与其他常见的血栓友突变相当或超过.
- 这些发现突出了JAK2突变CHIP作为VTE的关键风险因素,在没有确诊的骨髓质恶性瘤的情况下.
相关概念视频
01:24Disorders of Hemostasis
768
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
768
02:45Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
01:19Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
01:22Bone Marrow Sampling and Transplants
317
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
317
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:21Hematopoiesis
5.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.2K